株式会社グローバルインフォメーション
TEL: 044-952-0102
市場調査レポート

主要7カ国のサイトメガロウイルス (CMV) 感染症:疫学的予測

Cytomegalovirus (CMV) Infections - Epidemiology Forecast-2028

発行 DelveInsight Business Research LLP 商品コード 402149
出版日 ページ情報 英文 109 Pages
納期: 即日から翌営業日
価格
本日の銀行送金レート: 1USD=109.82円で換算しております。
Back to Top
主要7カ国のサイトメガロウイルス (CMV) 感染症:疫学的予測 Cytomegalovirus (CMV) Infections - Epidemiology Forecast-2028
出版日: 2019年09月01日 ページ情報: 英文 109 Pages
概要

当レポートでは、主要7カ国におけるサイトメガロウイルス (CMV) の感染動向を調査し、疾患の背景、臨床症状、リスク要因、病態生理、主要7カ国 (米国・ドイツ・フランス・イタリア・スペイン・英国・日本) における総有病者数、ハイリスク新生児、移植患者およびHIV患者における感染者数、抗体保有者数の推移と予測などをまとめています。

第1章 重要考察

第2章 疾患概要:サイトメガロウイルス (CMV) 感染症

  • イントロダクション
  • CMV感染症の臨床症状
  • 病因
  • リスク要因
  • 遺伝パターン
  • 兆候・症状
  • 病態生理
    • 遺伝子型解析
  • 診断
    • 鑑別診断
    • 診断基準
    • 勧告

第3章 疫学・患者人口

  • 主要調査結果
  • 人口・予測パラメーター

第4章 主要7カ国の総有病者数

第5章 CMV感染症の疫学:国別

  • 米国
    • 有病者人口
    • 有病者人口:区分別
    • 有病者人口:デノボ変異
  • ドイツ
    • 有病者人口
    • 有病者人口:区分別
    • 有病者人口:デノボ変異
  • フランス
    • 有病者人口
    • 有病者人口:区分別
    • 有病者人口:デノボ変異
  • イタリア
    • 有病者人口
    • 有病者人口:区分別
    • 有病者人口:デノボ変異
  • スぺイン
    • 有病者人口
    • 有病者人口:区分別
    • 有病者人口:デノボ変異
  • 英国
    • 有病者人口
    • 有病者人口:区分別
    • 有病者人口:デノボ変異
  • 日本
    • 有病者人口
    • 有病者人口:区分別
    • 有病者人口:デノボ変異

第6章 付録

第7章 DelveInsightの能力

第8章 免責事項

第9章 DelveInsightについて

図表

List of Tables

  • Table 1 List of diseases associated with HCMV (Human Cytomegalovirus)
  • Table 2 Total Sero-Prevalence of Cytomegalovirus Infection in 7MM (2017-2028)
  • Table 3 Total Diagnosed CMV Patients in 7MM (2017-2028)
  • Table 4 Total Diagnosed Cases of Cytomegalovirus (CMV) Infection in the United States (2017-2028)
  • Table 5 Number of Infants born with Congenital CMV in the United States (2017-2028)
  • Table 6 CMV Patients among Hematopoietic Stem Cell Transplants (HSCT) in the US (2017-2028)
  • Table 7 Number of CMV Patients among SOT in the United States (2017-2028)
  • Table 8 Number of Refractory CMV Patients after HSCT/SOT in the United States (2017-2028)
  • Table 9 CMV Retinitis among HIV Patients in the United States (2017-2028)
  • Table 10 Total Diagnosed Cases of Cytomegalovirus (CMV) Infection in Germany (2017-2028)
  • Table 11 Number of Infants born with Congenital CMV in Germany (2017-2028)
  • Table 12 CMV Patients among Hematopoietic Stem Cell Transplants (HSCT)in Germany (2017-2028)
  • Table 13 Number of CMV Patients among SOT in Germany (2017-2028)
  • Table 14 Number of Refractory CMV Patients after HSCT/SOT in Germany (2017-2028)
  • Table 15 CMV Retinitis among HIV Patients in Germany (2017-2028)
  • Table 16 Total Diagnosed Cases of Cytomegalovirus (CMV) Infection in France (2017-2028)
  • Table 17 Number of Infants born with Congenital CMV in France (2017-2028)
  • Table 18 CMV Patients among Hematopoietic Stem Cell Transplants (HSCT) in France (2017-2028)
  • Table 19 Number of CMV Patients among SOT in France (2017-2028)
  • Table 20 Number of Refractory CMV Patients after HSCT/SOT in France (2017-2028)
  • Table 21 CMV Retinitis among HIV Patients in France (2017-2028)
  • Table 22 Total Diagnosed CMV Patients in Italy (2017-2028)
  • Table 23 Number of Infants born with Congenital CMV in Italy (2017-2028)
  • Table 24 CMV Patients among Hematopoietic Stem Cell Transplants (HSCT) in Italy (2017-2028)
  • Table 25 Number of CMV Patients among SOT in Italy (2017-2028)
  • Table 26 Number of Refractory CMV Patients after HSCT/SOT in Italy (2017-2028) (2017-2028)
  • Table 27 CMV Retinitis among HIV Patients in Italy (2017-2028)
  • Table 28 Total Diagnosed CMV Patients in Spain (2017-2028)
  • Table 29 Number of Infants born with Congenital CMV in Spain 2017-2028)
  • Table 30 CMV Patients among Hematopoietic Stem Cell Transplants (HSCT) in Spain (2017-2028)
  • Table 31 Number of CMV Patients among SOT in Spain (2017-2028)
  • Table 32 Number of Refractory CMV Patients after HSCT/SOT in Spain (2017-2028)
  • Table 33 CMV Retinitis among HIV Patients in Spain (2017-2028)
  • Table 34 Total Diagnosed Cases of Cytomegalovirus (CMV) Infection in the United Kingdom (2017-2028)
  • Table 35 Number of Infants born with Congenital CMV in the UK (2017-2028)
  • Table 36 CMV Patients among Hematopoietic Stem Cell Transplants (HSCT) in the UK (2017-2028)
  • Table 37 Number of CMV Patients among SOT in the United Kingdom (2017-2028)
  • Table 38 Number of Refractory CMV Patients after HSCT/SOT in the UK (2017-2028)
  • Table 39 CMV Retinitis among HIV Patients in the UK (2017-2028)
  • Table 40 Total Diagnosed Cases of Cytomegalovirus (CMV) Infection in Japan (2017-2028)
  • Table 41 Number of Infants born with Congenital CMV in Japan (2017-2028)
  • Table 42 CMV Patients among HSCT Patients in Japan (2017-2028)
  • Table 43 Number of CMV Patients among SOT in Japan (2017-2028)
  • Table 44 Number of Refractory CMV Patients after HSCT/SOT in Japan (2017-2028)
  • Table 45 CMV Retinitis among HIV Patients in Japan (2017-2028)

List of Figures

  • Figure 1 Classification of CMV
  • Figure 2 Risk Factors CMV infection
  • Figure 3 Mechanisms used by Human cytomegalovirus to interfere with cell-mediated immunity
  • Figure 4 Impact of the immune system on CMV
  • Figure 5 CMV Disease Mechanisms
  • Figure 6 Total Sero Prevalence of Cytomegalovirus Infection in 7MM (2017-2028)
  • Figure 7 Total Diagnosed CMV Patients in 7MM (2017-2028)
  • Figure 8 Total Diagnosed Cases of Cytomegalovirus (CMV) Infection in the United States (2017-2028)
  • Figure 9 Number of Infants born with Congenital CMV in the United States (2017-2028)
  • Figure 10 CMV Patients among Hematopoietic Stem Cell Transplants (HSCT) in the US (2017-2028)
  • Figure 11 Number of CMV Patients among SOT in the United States (2017-2028)
  • Figure 12 Number of Refractory CMV Patients after HSCT/SOT in the United States (2017-2028)
  • Figure 13 CMV Retinitis among HIV Patients in the United States (2017-2028)
  • Figure 14 Total Diagnosed Cases of Cytomegalovirus (CMV) Infection in Germany (2017-2028)
  • Figure 15 Number of Infants born with Congenital CMV in Germany (2017-2028)
  • Figure 16 CMV Patients among Hematopoietic Stem Cell Transplants (HSCT) in Germany (2017-2028)
  • Figure 17 Number of CMV Patients among SOT in Germany (2017-2028)
  • Figure 18 Number of Refractory CMV Patients after HSCT/SOT in Germany (2017-2028)
  • Figure 19 CMV Retinitis among HIV Patients in Germany (2017-2028)
  • Figure 20 Total Diagnosed Cases of Cytomegalovirus (CMV) Infection in France (2017-2028)
  • Figure 21 Number of Infants born with Congenital CMV in France (2017-2028)
  • Figure 22 CMV Patients among Hematopoietic Stem Cell Transplants (HSCT) in France (2017-2028)
  • Figure 23 Number of CMV Patients among SOT in France (2017-2028)
  • Figure 24 Number of Refractory CMV Patients after HSCT/SOT in France (2017-2028)
  • Figure 25 CMV Retinitis among HIV Patients in France (2017-2028)
  • Figure 26 Total Diagnosed CMV Patients in Italy (2017-2028)
  • Figure 27 Number of Infants born with Congenital CMV in Italy (2017-2028)
  • Figure 28 CMV Patients among Hematopoietic Stem Cell Transplants (HSCT) in Italy (2017-2028)
  • Figure 29 Number of CMV Patients among SOT in Italy (2017-2028)
  • Figure 30 Number of Refractory CMV Patients after HSCT/SOT in Italy (2017-2028)
  • Figure 31 CMV Retinitis among HIV Patients in Italy (2017-2028)
  • Figure 32 Total Diagnosed CMV Patients in Spain (2017-2028)
  • Figure 33 Number of Infants born with Congenital CMV in Spain (2017-2028)
  • Figure 34 CMV Patients among Hematopoietic Stem Cell Transplants (HSCT) in Spain (2017-2028)
  • Figure 35 Number of CMV Patients among SOT in Spain (2017-2028)
  • Figure 36 Number of Refractory CMV Patients after HSCT/SOT in Spain (2017-2028)
  • Figure 37 HIV Patients at High Risk of CMV in Spain (2017-2028)
  • Figure 38 Total Diagnosed Cases of Cytomegalovirus (CMV) Infection in the United Kingdom (2017-2028)
  • Figure 39 Number of Infants born with Congenital CMV in the UK (2017-2028)
  • Figure 40 CMV Patients among Hematopoietic Stem Cell Transplants (HSCT) in the UK (2017-2028)
  • Figure 41 Number of CMV Patients among SOT in the UK (2017-2028)
  • Figure 42 Number of Refractory CMV Patients after HSCT/SOT in the United Kingdom (2017-2028)
  • Figure 43 CMV Retinitis among HIV Patients in the UK (2017-2028)
  • Figure 44 Total Diagnosed Cases of Cytomegalovirus (CMV) Infection in Japan (2017-2028)
  • Figure 45 Number of Infants born with Congenital CMV in Japan (2017-2028)
  • Figure 46 CMV Patients among HSCT in Japan (2017-2028)
  • Figure 47 Number of CMV Patients among SOT in Japan (2017-2028)
  • Figure 48 Number of Refractory CMV Patients after HSCT/SOT in Japan (2017-2028)
  • Figure 49 CMV Retinitis among HIV Patients in Japan (2017-2028)
目次
Product Code: DIEI0007

DelveInsight's 'Cytomegalovirus (CMV) Infections - Epidemiology Forecast-2028' report delivers an in-depth understanding of the disease, historical & forecasted epidemiology trends of Cytomegalovirus (CMV) Infections in the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.

There are certain groups at high risk for serious complications from CMV infection which includes: Pregnant Women, Transplant Patients with compromised immune systems, Patients with HIV, and Very low birth weight and premature infants.

Geography Covered

  • The United States
  • EU5 (Germany, France, Italy, Spain, and the United Kingdom)
  • Japan

Study Period: 2017-2028

Cytomegalovirus (CMV) Infections - Disease Understanding

Cytomegalovirus (CMV) is a commonly acquired infection and a member of the Herpesviridae family. Cytomegalovirus infection (CMV) is a viral infection that rarely causes obvious illness. There are three main types of CMV infections: acquired, recurring, or congenital. When the infection develops for the first time it is called acquired CMV. Recurrent CMV infection is defined as a new CMV infection in a patient with previous evidence of CMV infection in whom the virus has not been detected for at least 4 weeks during active surveillance. If a pregnant woman has an active CMV infection, the virus can be passed to the unborn baby and when it affects a baby in the womb, it's known as congenital CMV.

Cytomegalovirus (CMV) Infections - Epidemiology

The disease epidemiology covered in the report provides historical as well as forecasted epidemiology (Total Seroprevalence of CMV in 7MM, Total Diagnosed Cases of Cytomegalovirus (CMV) Infection in 7MM, Number of Infants born with Congenital CMV in 7MM, CMV Patients among Hematopoietic Stem Cell Transplants (HSCT) in 7MM, Number of CMV Patients among Solid Organ Transplants (SOT) in 7MM, Number of Refractory CMV Patients after HSCT/SOT in 7MM and CMV Retinitis among HIV Patients in 7MM) scenario of Cytomegalovirus (CMV) Infections in the 7MM covering United States, EU5 countries (Germany, Spain, Italy, France and United Kingdom) and Japan from 2017-2028.

According to DelveInsight, the total diagnosed cases of CMV were found out to be approximately 110,540 in the 7MM. The number of CMV cases in the 7MM is expected to increase during the study period of 2017-2028.

The estimates suggest higher diagnosed cases of CMV in the United States with around 70,207 cases in 2017. Among the European countries, France had the highest diagnosed cases of CMV with approximately 8,920 cases, followed by the United Kingdom which had diagnosed population of around 7,420 in 2017. On the other hand, Italy had the lowest diagnosed incident population of approximately 3,850 in 2017.

In the US, the total number of HSCT (allogeneic HSCT) patients were found out to be approximately 9,470 in 2017. It has been observed that approximately 46.94% of total HSCT (Allogeneic) patients are diagnosed with CMV. According to DelveInsight estimates, out of the total HSCT (allogeneic) patients, the number of CMV patients were found out to be around 4,407 in 2017.

Cytomegalovirus (CMV) Infections Report Insights

  • The report covers a descriptive overview of the Cytomegalovirus (CMV) Infections, explaining its causes, risk factors, pathophysiology, and diagnosis.
  • Comprehensive insight has been provided into the epidemiology Cytomegalovirus (CMV) Infections in the 7MM countries covering the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan.
  • Assesses growth opportunities in 7MM countries with respect to the patient population.

Cytomegalovirus (CMV) Infections Report Key Strengths

  • 10 Year Forecast
  • 7MM Coverage
  • Epidemiology Segmentation by Total diagnosed cases
  • Number of Infants born with Congenital CMV
  • CMV Patients among Hematopoietic Stem Cell Transplants (HSCT)
  • Number of CMV Patients among Solid Organ Transplants (SOT)
  • Number of Refractory CMV Patients after HSCT/SOT
  • CMV Retinitis among HIV Patients

Key Benefits

  • Key assessments
  • Patient Segmentation
  • Disease Risk & Burden
  • Risk of disease by Severity

Table of Contents

1. Key Insight

2. Cytomegalovirus (CMV) Infections Patient Overview at a Glance

  • 2.1. Patient Share (%) Distribution of Cytomegalovirus (CMV) Infections in 2017
  • 2.2. Patient Share (%) Distribution of Cytomegalovirus (CMV) Infections in 2028

3. Disease Background and Overview: Cytomegalovirus Infections (CMV)

  • 3.1. Introduction
  • 3.2. Classification of Cytomegalovirus Infections (CMV)
  • 3.3. Causes of CMV infections
  • 3.4. Symptoms of CMV infections
  • 3.5. Risk factors of CMV infections
  • 3.6. Pathophysiology of CMV infections
  • 3.7. Diagnosis of CMV infections

4. Epidemiology and Patient Population

  • 4.1. Key Findings
  • 4.2. Forecast Methodology
  • 4.3. Forecasting Assumptions
  • 4.4. Total Sero-Prevalence of CMV in 7MM
  • 4.5. Total Diagnosed CMV Patients in 7MM

5. Country Wise-Epidemiology of CMV Infections

  • 5.1. United States
    • 5.1.1. Assumptions and Rationale
    • 5.1.2. Total Diagnosed Cases of Cytomegalovirus (CMV) Infection in the United States
    • 5.1.3. Number of Infants born with Congenital CMV in the United States
    • 5.1.4. CMV Patients among Hematopoietic Stem Cell Transplants (HSCT) in the United States
    • 5.1.5. Number of CMV Patients among Solid Organ Transplants (SOT) in the United States
    • 5.1.6. Number of Refractory CMV Patients after HSCT/SOT in the United States
    • 5.1.7. CMV Retinitis among HIV Patients in the United States
  • 5.2. EU5 Countries
    • 5.2.1. Assumptions and Rationale
    • 5.2.2. Germany
      • 5.2.2.1. Total Diagnosed Cases of Cytomegalovirus (CMV) Infection in Germany
      • 5.2.2.2. Number of Infants born with Congenital CMV in Germany
      • 5.2.2.3. CMV Patients among Hematopoietic Stem Cell Transplants (HSCT) in Germany
      • 5.2.2.4. Number of CMV Patients among Solid Organ Transplants (SOT) in Germany
      • 5.2.2.5. Number of Refractory CMV Patients after HSCT/SOT in Germany
      • 5.2.2.6. CMV Retinitis among HIV Patients in Germany
    • 5.2.3. France
      • 5.2.3.1. Total Diagnosed Cases of Cytomegalovirus (CMV) Infection in France
      • 5.2.3.2. Number of Infants born with Congenital CMV in France
      • 5.2.3.3. CMV Patients among Hematopoietic Stem Cell Transplants (HSCT) in France
      • 5.2.3.4. Number of CMV Patients among Solid Organ Transplants (SOT) in France
      • 5.2.3.5. Number of Refractory CMV Patients after HSCT/SOT in France
      • 5.2.3.6. CMV Retinitis among HIV Patients in France
    • 5.2.4. Italy
      • 5.2.4.1. Total Diagnosed Cases of Cytomegalovirus (CMV) Infection in Italy
      • 5.2.4.2. Number of Infants born with Congenital CMV in Italy
      • 5.2.4.3. CMV Patients among Hematopoietic Stem Cell Transplants (HSCT) in Italy
      • 5.2.4.4. Number of CMV Patients among Solid Organ Transplants (SOT) in Italy
      • 5.2.4.5. Number of Refractory CMV Patients after HSCT/SOT in Italy
      • 5.2.4.6. CMV Retinitis among HIV Patients in Italy
    • 5.2.5. Spain
      • 5.2.5.1. Total Diagnosed Cases of Cytomegalovirus (CMV) Infection in Spain
      • 5.2.5.2. Number of Infants born with Congenital CMV in Spain
      • 5.2.5.3. CMV Patients among Hematopoietic Stem Cell Transplants (HSCT) in Spain
      • 5.2.5.4. Number of CMV Patients among Solid Organ Transplants (SOT) in Spain
      • 5.2.5.5. Number of Refractory CMV Patients after HSCT/SOT in Spain
      • 5.2.5.6. CMV Retinitis among HIV Patients in Spain
    • 5.2.6. United Kingdom
      • 5.2.6.1. Total Diagnosed Cases of Cytomegalovirus (CMV) Infection in the United Kingdom
      • 5.2.6.2. Number of Infants born with Congenital CMV in the United Kingdom
      • 5.2.6.3. CMV Patients among Hematopoietic Stem Cell Transplants (HSCT) in the United Kingdom
      • 5.2.6.4. Number of CMV Patients among Solid Organ Transplants (SOT) in the United Kingdom
      • 5.2.6.5. Number of Refractory CMV Patients after HSCT/SOT in the United Kingdom
      • 5.2.6.6. CMV Retinitis among HIV Patients in the United Kingdom
  • 5.3. Japan
    • 5.3.1. Assumptions and Rationale
    • 5.3.2. Total Diagnosed Cases of Cytomegalovirus (CMV) Infection in Japan
    • 5.3.3. Number of Infants born with Congenital CMV in Japan
    • 5.3.4. CMV Patients among Hematopoietic Stem Cell Transplants (HSCT) in Japan
    • 5.3.5. Number of CMV Patients among Solid Organ Transplants (SOT) in Japan
    • 5.3.6. Number of Refractory CMV Patients after HSCT/SOT in Japan
    • 5.3.7. CMV Retinitis among HIV Patients in Japan

6. Treatment Algorithm

  • 6.1. Canadian society of transplantation consensus workshop on Cytomegalovirus Management in Solid Organ Transplantation Final Report, 2005
  • 6.2. The Third International Consensus Guidelines on the management of Cytomegalovirus in Solid Organ Transplantation
  • 6.3. The Prevention and Management of CMV Disease after Solid Organ Transplantation: British Transplantation Society (2015)
  • 6.4. Guidelines for the management of cytomegalovirus infection in patients with haematological malignancies and after stem cell transplantation from the 2017 European Conference on Infections in Leukaemia (ECIL 7)
  • 6.5. Treatment of Cytomegalovirus(CMV)infection post renal transplantation (The guidelines for CMV infection post renal transplantation in Japanese Society for Clinical Renal Transplantation)
  • 6.6. Congenital Cytomegalovirus A European Expert Consensus Statement on Diagnosis and Management

7. Appendix

  • 7.1. Report Methodology

8. DelveInsight Capabilities

9. Disclaimer

10. About DelveInsight

Back to Top